Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Piperacillin/Tazobactam (ZOSYN).

Literature DB >> 18476104

Piperacillin/Tazobactam (ZOSYN).

S M Culver¹, M G Martens.

Abstract

Entities: Chemical

Year: 1996 PMID： 18476104 PMCID： PMC2364504 DOI： 10.1155/S1064744996000506

Source DB: PubMed Journal: Infect Dis Obstet Gynecol ISSN： 1064-7449

× No keyword cloud information.

16 in total

1. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery.

Authors: M Kinzig; F Sörgel; B Brismar; C E Nord
Journal: Antimicrob Agents Chemother Date: 1992-09 Impact factor: 5.191

2. In vitro effect of YTR (tazobactam) on plasmid and chromosomally mediated beta-lactamases.

Authors: E E Stobberingh
Journal: Chemotherapy Date: 1990 Impact factor: 2.544

3. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.

Authors: M Akova; Y Yang; D M Livermore
Journal: J Antimicrob Chemother Date: 1990-02 Impact factor: 5.790

4. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.

Authors: F Higashitani; A Hyodo; N Ishida; M Inoue; S Mitsuhashi
Journal: J Antimicrob Chemother Date: 1990-04 Impact factor: 5.790

5. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.

Authors: R N Jones; M A Pfaller; P C Fuchs; K Aldridge; S D Allen; E H Gerlach
Journal: Diagn Microbiol Infect Dis Date: 1989 Nov-Dec Impact factor: 2.803

6. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers.

Authors: E J Baron; R N Jones
Journal: Diagn Microbiol Infect Dis Date: 1995-03 Impact factor: 2.803

Piperacillin/Tazobactam (ZOSYN).

1. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery.

2. In vitro effect of YTR (tazobactam) on plasmid and chromosomally mediated beta-lactamases.

3. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.

4. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.

5. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.

6. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers.

7. Diverse potential of beta-lactamase inhibitors to induce class I enzymes.

8. Infectious disease relations to cesarean section.

9. Comparative study of piperacillin versus cefoxitin in the treatment of obstetric and gynecologic infections.

Review 10. Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections.